2301-40-8

Basic information

• Product Name: 2,4-Imidazolidinedione, 3-(phenylmethyl)-
• CAS NO: 2301-40-8
• Molecular Formula: C10H10N2O2
• Molecular Weight: 190.202
• Mol File: 2301-40-8.mol
• Article Data: 19

Chemical Properties

• CAS DataBase Reference: 2,4-Imidazolidinedione, 3-(phenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Imidazolidinedione, 3-(phenylmethyl)-(2301-40-8)
• EPA Substance Registry System: 2,4-Imidazolidinedione, 3-(phenylmethyl)-(2301-40-8)

Safety Data

• Hazardous Substances Data: 2301-40-8(Hazardous Substances Data)

Usage

General Description

2,4-Imidazolidinedione, 3-(phenylmethyl)-, also known as phenytoin, is an anticonvulsant medication used to control seizures. It works by slowing down electrical activity in the brain that can cause seizures. Phenylmethyl-2,4-imidazolidinedione is available in both oral and injectable forms, and is often used to treat various types of seizures, including complex partial seizures and generalized tonic-clonic seizures. It is also used to prevent seizures during or after surgery on the nervous system. Common side effects of this medication include dizziness, drowsiness, slurred speech, and headache, and it may also cause more serious side effects such as a rare but severe skin reaction known as Stevens-Johnson syndrome. It is important for patients to follow their doctor's instructions and be monitored regularly while taking phenylmethyl-2,4-imidazolidinedione to ensure its safety and effectiveness.

Upstream product

• 461-72-3 2,4-imidazolidinedione 
• 100-39-0 benzyl bromide 
• 3173-56-6 benzyl isothiocyanate 
• 22003-17-4 O-phenyl N-benzylcarbamate 
• 5680-79-5 glycine ethyl ester hydrochloride 
• 25370-09-6 dibenzylcarbamyl chloride 
• 23583-12-2 N-benzyl-2-(3-benzylureido)acetamide 
• 1538-75-6 2,2-dimethylpropanoic anhydride 
• 1128079-90-2 tert-butyl-3-benzyl-2,4-dioxoimidazolidine-1-carboxylate 
• 100-44-7 benzyl chloride 

Downstream Products

• 123944-80-9 3-Benzyl-1-(4-nitrobenzyl)imidazolidin-2,4-dione 
• 1398413-41-6 1,5-diallyl-3-benzylimidazolidine-2,4-dione 
• 1398413-45-0 3-benzyl-1,5-bis(2-methylallyl)imidazolidine-2,4-dione 
• 1398413-51-8 1-allyl-3-benzyl-5-(but-3-enyl)imidazolidine-2,4-dione 
• 1398413-55-2 1-allyl-3-benzyl-5-(pent-4-enyl)imidazolidine-2,4-dione 
• 1398413-83-6 3-benzyl-1,3-diazaspiro[4.4]non-7-ene-2,4-dione 
• 1398414-13-5 2-benzyl-8,8a-dihydroimidazo[1,5-a]pyridine-1,3(2H,5H)-dione 
• 1398414-17-9 2-benzyl-6,7-dimethyl-8,8a-dihydroimidazo[1,5-a]pyridine-1,3-(2H,5H)-dione 
• 1398413-27-8 3-benzyl-1-(2-methylallyl)imidazolidine-2,4-dione 
• 551939-95-8 1-allyl-3-benzylimidazolidine-2,4-dione 
• 1398413-31-4 5,5-diallyl-3-benzylimidazolidine-2,4-dione 

Relevant articles and documents

One-Pot Oxidation of Secondary Alcohols to α-Hydroxy Ketones: Application to Synthesis of Oxoaplysinopsin D, E, F, & G

A simple one-pot transformation of secondary alcohols to α-hydroxy ketones using pyridinium dichromate (PDC) in DMF has been developed and substrate scope tested with 25 compounds of hydantoin derivatives. Using this method, we have devised a common dihyd

Design, synthesis and biological evaluation of novel 5-((substituted quinolin-3-yl/1-naphthyl) methylene)-3-substituted imidazolidin-2,4-dione as HIV-1 fusion inhibitors

A series of novel 5-(substituted quinolin-3-yl or 1-naphthyl)methylene)-3-substituted imidazolidin-2,4-dione 9–26 was designed and synthesized. The prepared compounds were identified using 1H NMR, 13C NMR as well as elemental analyses. The inhibitory activity of 9–26 on HIV-1IIIB replication in MT-2 cells was evaluated. Some derivatives showed good to excellent anti-HIV activities as compounds 13, 18, 19, 20, 22 and 23. They showed EC50 of 0.148, 0.460, 0.332, 0.50, 0.271 and 0.420 μM respectively being more potent than compound I (EC50 = 0.70 μM) and II ( EC50 = 2.40 μM) as standards. The inhibitory activity of 9–26 on infected primary HIV-1 domain, 92US657 (clade B, R5) was investigated. All the tested compounds consistently inhibited infection of this virus with EC50 from 0.520 to 11.857 μM. Results from SAR studies showed that substitution on ring A with 6/7/8-methyl group resulted in significant increase in the inhibitory activity against HIV-1IIIB infection (5- >300 times) compared to the unsubstituted analog 9. The cytotoxicity of these compounds on MT-2 cells was tested and their CC50 values ranged from 11 to 85 μM with selectivity indexes ranged from 0.53 to 166. The docking study revealed nice fitting of the new compounds into the hydrophobic pocket of HIV-1 gp41 and higher affinity than NB-64. Compound 13, the most active in preventing HIV-1IIIB infection, adopted a similar orientation to compound IV. Molecular docking analysis of the new compounds revealed hydrogen bonding interactions between the imidazolidine-2,4-dione ring and LYS574 which were missed in the weakly active derivatives.

HETEROCYCLIC INTEGRIN AGONISTS

The present invention provides polycyclic oxothioxoimidazolidines, dioxoimidazolines, oxothioxooxazolidines, dioxooxazolidines, and related compounds, which are useful as integrin agonists. Methods for the treatment of integrin-mediated diseases such as cancer are also described.